A small-molecule USP30 inhibitor protects against doxorubicin-induced cardiomyopathy
TS-075254 — Problem
Cardiomyopathy weakens the heart muscle and impairs its ability to pump blood effectively, often leading to heart failure or sudden cardiac death. While doxorubicin remains an essential component of many cancer regimens, its use is limited by the risk of causing lethal cardiomyopathy. A maj…
- College: College
of
Medicine
(COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
Identification of DNA methylation profiles for targeted therapy in Acute Myeloid Leukemia and other cancers
TS-075244 — Problem
Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a clinically and molecularly heterogeneous disease. Sequencing of large patient cohorts has uncovered a complex mutational landscape in AML but still fails to completely explain the biological and clinical heterogene…
- College: College
of
Medicine
(COM)
- Inventors: Oakes, Christopher; Blachly, James; Byrd, John
- Licensing Officer: Schworer, Adam
Anti-GARP monoclonal antibody enhances anti-cancer therapeutics
TS-075242 — THE PROBLEM
Although immune checkpoint blockade (ICB) has emerged as promising cancer immunotherapy, many tumors fail to respond to ICB. This failed response is often driven by the activation of TGF-β1 in the tumor microenvironment (TME), which induces regulatory T cells and inhibits the funct…
- College: College
of
Medicine
(COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
A novel class of small, drug-like compounds for the treatment of human liposarcoma
TS-075240 — Problem
Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with limited effective treatment options and a dismal prognosis. Current therapies often fail due to tumor resistance, poor specificity, and toxicity. The aggressive clinical behavior of LPS and its resistance to chem…
- College: College
of
Medicine
(COM)
- Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
- Licensing Officer: Willson, Christopher
Unleashing the Power of Radiotherapy – Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-075239 — Papaverine is an FDA-approved potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been shown to be responsible for increased oxygenation and enhanced radiation response. However, papaverine is also a phosphodiesterase 10A (PDE10A) inhibitor with pot…
- College: College
of
Medicine
(COM)
- Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
- Licensing Officer: Willson, Christopher
Biomarker for prediction of immunotherapy outcomes and precision treatment strategies
TS-075237 — Problem
The loss or mutation of serine/threonine kinase 11 (STK11), observed in 20–25% of non-small cell lung cancer (NSCLC) cases, is associated with poor prognosis and resistance to immune checkpoint blockade (ICB). While STK11 alterations are commonly linked to immunotherapy resistance, so…
- College: College
of
Medicine
(COM)
- Inventors: Kaufman, Jacob
- Licensing Officer: Willson, Christopher
Small molecule inhibitor of the Ral small G proteins for triple-negative breast cancer (TNBC)
TS-075232 — Problem
Breast cancer (BC) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death among women in the United States. Within its subtypes, triple-negative breast cancer (TNBC) carries the highest mortality, driven in large part by a lack of effective targeted t…
- College: College
of
Medicine
(COM)
- Inventors: Sizemore, Steven; Lindert, Steffen
- Licensing Officer: Bhatti, Hamid
Next-gen AAV-delivered anti-GARP/CD3 BiTCE for treatment of hematological and solid tumors
TS-075191 — PROBLEM
Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…
- College: College
of
Medicine
(COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
A novel approach to reverse T cell exhaustion to improve anti-cancer and anti-viral responses
TS-075186 — PROBLEM
Exhausted CD8 T cells significantly limit the effectiveness of immunotherapies and cell therapies in cancer and chronic viral infections. Persistent antigen exposure drives durable epigenetic reprogramming that locks T cells into a dysfunctional state, silencing effector and memory-associat…
- College: College
of
Medicine
(COM)
- Inventors: Ghoneim, Hazem
- Licensing Officer: He, Panqing
Show More Technologies
